1. Home
  2. TNON vs SNTI Comparison

TNON vs SNTI Comparison

Compare TNON & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenon Medical Inc.

TNON

Tenon Medical Inc.

HOLD

Current Price

$0.91

Market Cap

4.8M

Sector

Health Care

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

SELL

Current Price

$2.00

Market Cap

5.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TNON
SNTI
Founded
2012
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
5.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TNON
SNTI
Price
$0.91
$2.00
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$6.00
★ $445.50
AVG Volume (30 Days)
95.4K
★ 1.2M
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 84.90
77.31
EPS
N/A
★ N/A
Revenue
★ $3,944,000.00
N/A
Revenue This Year
$44.38
$127.27
Revenue Next Year
$39.49
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 20.35
N/A
52 Week Low
$0.96
$0.09
52 Week High
$40.95
$57.60

Technical Indicators

Market Signals
Indicator
TNON
SNTI
Relative Strength Index (RSI) 22.15 62.11
Support Level N/A $0.15
Resistance Level $4.18 $7.00
Average True Range (ATR) 0.17 0.07
MACD -0.02 0.45
Stochastic Oscillator 4.65 74.91

Price Performance

Historical Comparison
TNON
SNTI

About TNON Tenon Medical Inc.

Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: